Paul W. Noble, MD, discusses key updates in treatment for idiopathic pulmonary fibrosis.
EP. 1: Symptoms, Manifestations and Mortality Rate of IPF
Paul Noble, MD, opens a discussion surrounding the current treatment landscape and key elements to address in the management of idiopathic pulmonary fibrosis.
Watch
EP. 2: How the GAP Program Helps Determine Patient Prognosis, and Risk Factors for Developing IPF/PPF
Paul Noble, MD, analyzes variables contributing to IPF or PPF disease prognosis.
EP. 3: Epidemiology Facts, Differential Diagnosis, and Arriving at a IPF or PPF Diagnosis
Paul Noble, MD, discusses epidemiology facts, differential diagnosis, and arriving at a IPF or PPF diagnosis.
EP. 4: Critical Early Diagnoses and Acute Exacerbations in IPF and PPF
Paul Noble, MD, discusses the importance of early diagnosis in patients with IPF or PPF.
EP. 5: Exploring the Role of Non-Pharmacological Modalities and Multidisciplinary Care in Patients with Idiopathic and Progressive Pulmonary Fibrosis
Dr. Paul Frohna discusses the importance of non-pharmacological modalities, as well as utilizing multidisciplinary care, for patients with idiopathic and progressive pulmonary fibrosis.
EP. 6: Managing Acute Exacerbations and the Psychosocial Aspect of Idiopathic and Progressive Pulmonary Fibrosis
An expert pulmonologist discusses the best ways to manage acute exacerbations and the psychosocial component of idiopathic and progressive pulmonary fibrosis.
EP. 7: Key Unmet Needs Associated with Idiopathic and Progressive Pulmonary Fibrosis
Dr. Frohna covers unmet needs in the latest treatment guidelines and therapies used to combat idiopathic and progressive pulmonary fibrosis.
EP. 8: The Roles of Biomarker Testing and HRCT in IPF and PPF
Paul Noble, MD, discusses the roles of biomarker testing and HRCT in IPF and PPF.
EP. 9: Unmet Needs and the Role of AI in Earlier Disease Detection
Paul Noble, MD, provides his final thoughts surrounding unmet needs and breakthrough strategies for detection of IPF.
EP. 10: Adverse Events Associated with Anti-Fibrotic Therapies
An expert lung doctor covers the main adverse events associated with antifibrotic agents and why it is necessary to develop newer pharmacotherapies to treat idiopathic and progressive pulmonary fibrosis.
EP. 11: Investigational Agents for Idiopathic and Progressive Pulmonary Fibrosis
Dr Frohna discusses some therapies under investigation for idiopathic and progressive pulmonary fibrosis, including one targeting the PDE4 pathway.
EP. 12: The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment
An expert physician discusses the potential role of novel agents in the management of idiopathic and progressive pulmonary fibrosis.
